English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214658
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions

AuthorsNeukam, Karin; Gutiérrez Valencia, Alicia; Llaves, Silvia; Espinosa, Nuria; Viciana, Pompeyo; López-Cortés, Luis F.
KeywordsHIV
Hepatitis B virus
Vaccination
CD4/CD8 ratio
Issue Date6-May-2019
PublisherElsevier
CitationVaccine 37(20): 2758-2763 (2019)
Abstract[Background] HIV-infected patients are at risk of hepatitis B virus (HBV) coinfection, however, respond worse to HBV vaccination (HBV-V) than immunocompetent adults. This study aimed to determine the response to reinforced HBV-V in HIV-infected subjects under real-life conditions.
[Methods] HIV-infected patients followed at a Spanish University Hospital who were seronegative for HBV and who received three double-doses (40 µL) of HBV-V at 0, 1 and 2 months were included. Response to HBV-V was defined as HBV surface antibody concentration of ≥10 IU/L 1–12 months after the last HBV-V dose.
[Results] Of 332 patients included in the study, 256 (77.1%) showed response to HBV-V. Median (interquartile range) CD4+/CD8+ ratio among the responders was 0.75 (0.52–1.01) versus 0.61 (0.38–0.84) among the non-responders (p = 0.002). Independent predictors for HBV-V response were: female gender [adjusted odds ratio (AOR): 6.240; 95% confidence interval (95%CI): 1.954–19.925; p = 0.002]; non-smoking [AOR: 2.151; 95%CI: 1.243–3.721; p = 0.006]; a CD4+/CD8+ ratio ≥0.67 [AOR: 2.580; 95%CI: 1.209–5.505; p = 0.014] and baseline HIV-RNA ≤50 copies/mL [AOR: 2.049; 95%CI: 1.098–3.824; p = 0.024].
[Conclusion] Accelerated administration of three double-doses results in considerable high, however still suboptimal, response rates to HBV-V in HIV-infected patients in the clinical practice. A fourth dose should be considered.
Publisher version (URL)http://dx.doi.org/10.1016/j.vaccine.2019.03.029
URIhttp://hdl.handle.net/10261/214658
DOIhttp://dx.doi.org/10.1016/j.vaccine.2019.03.029
Identifiersdoi: 10.1016/j.vaccine.2019.03.029
issn: 0264-410X
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.